Literature DB >> 24588402

Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.

Clare M Gladding1, Jing Fan, Lily Y J Zhang, Liang Wang, Jian Xu, Edward H Y Li, Paul J Lombroso, Lynn A Raymond.   

Abstract

Striatal neurodegeneration and synaptic dysfunction in Huntington's disease are mediated by the mutant huntingtin (mHtt) protein. MHtt disrupts calcium homeostasis and facilitates excitotoxicity, in part by altering NMDA receptor (NMDAR) trafficking and function. Pre-symptomatic (excitotoxin-sensitive) transgenic mice expressing full-length human mHtt with 128 polyglutamine repeats (YAC128 Huntington's disease mice) show increased calpain activity and extrasynaptic NMDAR (Ex-NMDAR) localization and signaling. Furthermore, Ex-NMDAR stimulation facilitates excitotoxicity in wild-type cortical neurons via calpain-mediated cleavage of STriatal-Enriched protein tyrosine Phosphatase 61 (STEP61). The cleavage product, STEP33, cannot dephosphorylate p38 mitogen-activated protein kinase (MAPK), thereby augmenting apoptotic signaling. Here, we show elevated extrasynaptic calpain-mediated cleavage of STEP61 and p38 phosphorylation, as well as STEP61 inactivation and reduced extracellular signal-regulated protein kinase 1/2 phosphorylation (ERK1/2) in the striatum of 6-week-old, excitotoxin-sensitive YAC128 mice. Calpain inhibition reduced basal and NMDA-induced STEP61 cleavage. However, basal p38 phosphorylation was normalized by a peptide disrupting NMDAR-post-synaptic density protein-95 (PSD-95) binding but not by calpain inhibition. In 1-year-old excitotoxin-resistant YAC128 mice, STEP33 levels were not elevated, but STEP61 inactivation and p38 and ERK 1/2 phosphorylation levels were increased. These results show that in YAC128 striatal tissue, enhanced NMDAR-PSD-95 interactions contributes to elevated p38 signaling in early, excitotoxin-sensitive stages, and suggest that STEP61 inactivation enhances MAPK signaling at late, excitotoxin-resistant stages. The YAC128 Huntington's disease mouse model shows early, enhanced susceptibility to NMDA receptor-mediated striatal apoptosis, progressing to late-stage excitotoxicity resistance. This study shows that elevated NMDA receptor-PSD-95 interactions as well as decreased extrasynaptic STriatal-Enriched protein tyrosine Phosphatase 61 (STEP61) activation may contribute to early enhanced apoptotic signaling. In late-stage YAC128 mice, reduced STEP61 levels and activity correlate with elevated MAPK signaling, consistent with excitotoxicity resistance. Solid and dotted arrows indicate conclusions drawn from the current study and other literature, respectively.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  Huntington's disease; NMDA receptor; STriatal-Enriched protein tyrosine Phosphatase; calpain; extrasynaptic; p38 mitogen-activated protein kinase signaling

Mesh:

Substances:

Year:  2014        PMID: 24588402      PMCID: PMC4065618          DOI: 10.1111/jnc.12700

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  42 in total

1.  Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.

Authors:  Michelle Aarts; Yitao Liu; Lidong Liu; Shintaro Besshoh; Mark Arundine; James W Gurd; Yu-Tian Wang; Michael W Salter; Michael Tymianski
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

2.  Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.

Authors:  Mannie M Y Fan; Herman B Fernandes; Lily Y J Zhang; Michael R Hayden; Lynn A Raymond
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

3.  NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling.

Authors:  Surojit Paul; Angus C Nairn; Ping Wang; Paul J Lombroso
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

4.  Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin.

Authors:  Y F Liu; D Dorow; J Marshall
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

5.  The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway.

Authors:  S Paul; G L Snyder; H Yokakura; M R Picciotto; A C Nairn; P J Lombroso
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

6.  Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420.

Authors:  Tri-Hung Nguyen; Jian Liu; Paul J Lombroso
Journal:  J Biol Chem       Date:  2002-04-30       Impact factor: 5.157

7.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways.

Authors:  G E Hardingham; Y Fukunaga; H Bading
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

8.  Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

Authors:  Melinda M Zeron; Oskar Hansson; Nansheng Chen; Cheryl L Wellington; Blair R Leavitt; Patrik Brundin; Michael R Hayden; Lynn A Raymond
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

9.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.

Authors:  Y J Kim; Y Yi; E Sapp; Y Wang; B Cuiffo; K B Kegel; Z H Qin; N Aronin; M DiFiglia
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

10.  Calpain activation in Huntington's disease.

Authors:  Juliette Gafni; Lisa M Ellerby
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

View more
  13 in total

1.  Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61 ) levels.

Authors:  Jian Xu; Pradeep Kurup; Garikoitz Azkona; Tyler D Baguley; Ana Saavedra; Angus C Nairn; Jonathan A Ellman; Esther Pérez-Navarro; Paul J Lombroso
Journal:  J Neurochem       Date:  2015-09-17       Impact factor: 5.372

Review 2.  Calcium signaling and molecular mechanisms underlying neurodegenerative diseases.

Authors:  Ekaterina Pchitskaya; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Cell Calcium       Date:  2017-06-30       Impact factor: 6.817

3.  PLK1 regulates spindle association of phosphorylated eukaryotic translation initiation factor 4E-binding protein and spindle function in mouse oocytes.

Authors:  Ashley L Severance; Keith E Latham
Journal:  Am J Physiol Cell Physiol       Date:  2018-02-22       Impact factor: 4.249

4.  Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.

Authors:  Carlos Cepeda; Michael S Levine
Journal:  Neuroscientist       Date:  2020-11-16       Impact factor: 7.235

5.  Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice.

Authors:  Jian Xu; Pradeep Kurup; Tyler D Baguley; Ethan Foscue; Jonathan A Ellman; Angus C Nairn; Paul J Lombroso
Journal:  Cell Mol Life Sci       Date:  2015-10-08       Impact factor: 9.261

6.  Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.

Authors:  Marja D Sepers; Amy Smith-Dijak; Jeff LeDue; Karolina Kolodziejczyk; Ken Mackie; Lynn A Raymond
Journal:  J Neurosci       Date:  2017-11-30       Impact factor: 6.167

7.  Physiological Roles of Calpain 1 Associated to Multiprotein NMDA Receptor Complex.

Authors:  Monica Averna; Matteo Pellegrini; Chiara Cervetto; Marco Pedrazzi; Margherita Bavestrello; Roberta De Tullio; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

8.  Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway.

Authors:  Wojciech J Szlachcic; Pawel M Switonski; Wlodzimierz J Krzyzosiak; Marek Figlerowicz; Maciej Figiel
Journal:  Dis Model Mech       Date:  2015-06-18       Impact factor: 5.758

Review 9.  Corticostriatal synaptic adaptations in Huntington's disease.

Authors:  Joshua L Plotkin; D James Surmeier
Journal:  Curr Opin Neurobiol       Date:  2015-02-18       Impact factor: 6.627

Review 10.  Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease.

Authors:  Laetitia Francelle; Laurie Galvan; Emmanuel Brouillet
Journal:  Front Cell Neurosci       Date:  2014-09-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.